This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Murakami-Kubo, I.
Right arrow Articles by Iwaki, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Murakami-Kubo, I.
Right arrow Articles by Iwaki, T.

 Previous Article  |  Next Article 

Journal of Virology, February 2004, p. 1281-1288, Vol. 78, No. 3
0022-538X/04/$08.00+0     DOI: 10.1128/JVI.78.3.1281-1288.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.

Quinoline Derivatives Are Therapeutic Candidates for Transmissible Spongiform Encephalopathies

Ikuko Murakami-Kubo,1,2* Katsumi Doh-ura,1* Kensuke Ishikawa,1 Satoshi Kawatake ,1,{dagger} Kensuke Sasaki,1 Jun-ichi Kira,2 Shigeru Ohta,3 and Toru Iwaki1

Departments of Neuropathology,1 Neurology, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812-8582,2 Department of Graduate School of Biomedical Science, Hiroshima University, Hiroshima 734-8551, Japan3

Received 2 June 2003/ Accepted 8 October 2003

We previously reported that quinacrine inhibited the formation of an abnormal prion protein (PrPres), a key molecule in the pathogenesis of transmissible spongiform encephalopathy, or prion disease, in scrapie-infected neuroblastoma cells. To elucidate the structural aspects of its inhibiting action, various chemicals with a quinoline ring were screened in the present study. Assays of the scrapie-infected neuroblastoma cells revealed that chemicals with a side chain containing a quinuclidine ring at the 4 position of a quinoline ring (represented by quinine) inhibited the PrPres formation at a 50% inhibitory dose ranging from 10-1 to 101 µM. On the other hand, chemicals with a side chain at the 2 position of a quinoline ring (represented by 2,2'-biquinoline) more effectively inhibited the PrPres formation at a 50% inhibitory dose ranging from 10-3 to 10-1 µM. A metabolic labeling study revealed that the action of quinine or biquinoline was not due to any alteration in the biosynthesis or turnover of normal prion protein, whereas surface plasmon resonance analysis showed a strong binding affinity of biquinoline with a recombinant prion protein. In vivo studies revealed that 4-week intraventricular infusion of quinine or biquinoline was effective in prolonging the incubation period in experimental mouse models of intracerebral infection. The findings suggest that quinoline derivatives with a nitrogen-containing side chain have the potential of both inhibiting PrPres formation in vitro and prolonging the incubation period of infected animals. These chemicals are new candidates for therapeutic drugs for use in the treatment of transmissible spongiform encephalopathies.

* Corresponding author. Mailing address for Ikuko Murakami-Kubo: Department of Neuropathology, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan. Phone: 81-92-642-5537. Fax: 81-92-642-5540. E-mail: i-muraka{at}np.med.kyushu-u.ac.jp. Mailing address for Katsumi Doh-ura: Department of Prion Research, Tohoku University Graduate School of Medicine, 2-1 Seiryo-cho, Aoba-ku, Sendai 980-8575, Japan. Phone: 81-22-717-8232. Fax: 81-22-717-8148. E-mail: doh-ura{at}mail.tains.tohoku.ac.jp.

{dagger} Present address: Department of Prion Research, Tohoku University Graduate School of Medicine, Sendai 980-8575, Japan.

Journal of Virology, February 2004, p. 1281-1288, Vol. 78, No. 3
0022-538X/04/$08.00+0     DOI: 10.1128/JVI.78.3.1281-1288.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Kawasaki, Y., Kawagoe, K., Chen, C.-j., Teruya, K., Sakasegawa, Y., Doh-ura, K. (2007). Orally Administered Amyloidophilic Compound Is Effective in Prolonging the Incubation Periods of Animals Cerebrally Infected with Prion Diseases in a Prion Strain-Dependent Manner. J. Virol. 81: 12889-12898 [Abstract] [Full Text]  
  • Trevitt, C. R, Collinge, J. (2006). A systematic review of prion therapeutics in experimental models. Brain 129: 2241-2265 [Abstract] [Full Text]  
  • Kocisko, D. A., Caughey, B. (2006). Mefloquine, an Antimalaria Drug with Antiprion Activity In Vitro, Lacks Activity In Vivo. J. Virol. 80: 1044-1046 [Abstract] [Full Text]  
  • Gobbi, M., Colombo, L., Morbin, M., Mazzoleni, G., Accardo, E., Vanoni, M., Del Favero, E., Cantu, L., Kirschner, D. A., Manzoni, C., Beeg, M., Ceci, P., Ubezio, P., Forloni, G., Tagliavini, F., Salmona, M. (2006). Gerstmann-Straussler-Scheinker Disease Amyloid Protein Polymerizes According to the "Dock-and-Lock" Model. J. Biol. Chem. 281: 843-849 [Abstract] [Full Text]  
  • Novakofski, J., Brewer, M. S., Mateus-Pinilla, N., Killefer, J., McCusker, R. H. (2005). Prion biology relevant to bovine spongiform encephalopathy. J ANIM SCI 83: 1455-1476 [Abstract] [Full Text]  
  • Kim, C.-L., Karino, A., Ishiguro, N., Shinagawa, M., Sato, M., Horiuchi, M. (2004). Cell-surface retention of PrPC by anti-PrP antibody prevents protease-resistant PrP formation. J. Gen. Virol. 85: 3473-3482 [Abstract] [Full Text]  
  • Ishikawa, K., Doh-ura, K., Kudo, Y., Nishida, N., Murakami-Kubo, I., Ando, Y., Sawada, T., Iwaki, T. (2004). Amyloid imaging probes are useful for detection of prion plaques and treatment of transmissible spongiform encephalopathies. J. Gen. Virol. 85: 1785-1790 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»